MaxCyte, Inc. (AIM:MXCT)

Market Cap	161.75M
Revenue (ttm)	29.16M
Net Income (ttm)	-32.35M
Shares Out	106.42M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,426
Average Volume	36,563
Open	157.50
Previous Close	160.00
Day's Range	147.69 - 160.00
52-Week Range	147.69 - 407.84
Beta	1.04
RSI	29.44
Earnings Date	Aug 6, 2025

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineer...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 114
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: MXCT

Financial Performance

In 2024, MaxCyte's revenue was $38.63 million, a decrease of -6.44% compared to the previous year's $41.29 million. Losses were -$41.06 million, 8.26% more than in 2023.

Financial numbers in USD